Press release: phase III SKYSCRAPER-01 study negative for OS at final analysis. Adding anti-TIGIT tiragolumab to first line atezolizumab in advanced PDL1 high NSCLC did not improve PFS or OS. Now to dissect what happened between phase II and III.
www.gene.com/media/press-...
gene.com
Genentech: Press Releases | Monday, Nov 25, 2024
Discover the latest news about our company, our products, our policies, and our people.
